42646-0 |
Ethambutol 5.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Ethambutol 5.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42646-0 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Ethambutol 5 ug/mL Islt SlowM |
|
|
|
N |
|
5 ug/mL; ANTIBIOTIC SUSCEPTIBILITIES; AST; Etambol; Ethamb; ID; Inagen; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myambutol; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42647-8 |
Ethionamide 10.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Ethionamide 10.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42647-8 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Ethionamide 10 ug/mL Islt Slo |
|
|
|
N |
|
10 ug/mL; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Trecator |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42648-6 |
Ethionamide 5.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Ethionamide 5.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42648-6 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Ethionamide 5 ug/mL Islt Slow |
|
|
|
N |
|
5 ug/mL; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Trecator |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42649-4 |
Isoniazid 0.2 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Isoniazid 0.2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42649-4 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Isoniazid 0.2 ug/mL Islt Slow |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Hyzyd; ID; Infectious Disease; InfectiousDisease; INH; Islt; Isol; Isoniaz; Isoniazide; mcg; Nudrazod; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
4265-5 |
Furfenorex |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Furfenorex [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4265-5 |
|
|
|
|
Observation |
|
|
|
0 |
Furfenorex Dose |
|
|
|
Y |
|
Addiction; Dose med or substance; DRUG DOSES; Drugs of abuse; Frugalan; Illicit; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
42650-2 |
Isoniazid 1.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Isoniazid 1.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42650-2 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Isoniazid 1 ug/mL Islt SlowMy |
|
|
|
N |
|
1 ug/mL; ANTIBIOTIC SUSCEPTIBILITIES; AST; Hyzyd; ID; Infectious Disease; InfectiousDisease; INH; Islt; Isol; Isoniaz; Isoniazide; mcg; Nudrazod; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42651-0 |
Isoniazid 5.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Method for Slow-growing mycobacteria |
|
ACTIVE |
Isoniazid 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42651-0 |
|
Method for Slow-growing mycobacteria |
|
|
Observation |
|
|
|
0 |
Isoniazid 5 ug/mL Islt SlowMyco |
|
|
|
N |
|
5 ug/mL; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; Hyzyd; ID; Infectious Disease; InfectiousDisease; INH; Islt; Isol; Isoniaz; Isoniazide; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Nudrazod; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis |
2.26 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42652-8 |
Kanamycin 5.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Kanamycin 5.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42652-8 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Kanamycin 5 ug/mL Islt SlowMy |
|
|
|
N |
|
5 ug/mL; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Kantrex; mcg; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42653-6 |
Ofloxacin 2.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Ofloxacin 2.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42653-6 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Ofloxacin 2 ug/mL Islt SlowMy |
|
|
|
N |
|
2 ug/mL; ANTIBIOTIC SUSCEPTIBILITIES; AST; c409; Floxin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42654-4 |
Para aminosalicylate 2.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Para aminosalicylate 2.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42654-4 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated PAS 2 ug/mL Islt SlowMyco |
|
|
|
N |
|
2 ug/mL; Aminosalicycic; Aminosalycilate; ANTIBIOTIC SUSCEPTIBILITIES; AST; Epusal; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; NA-PAS; Nemasol sodium; p-aminosalicyclic acid; Para aminosalicylic acid; PAS; Point in time; Random; Salf-pas; Sodico; Sodium PAS; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Therazid |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42655-1 |
Rifabutin 0.5 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Method for Slow-growing mycobacteria |
|
ACTIVE |
Rifabutin 0.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42655-1 |
|
Method for Slow-growing mycobacteria |
|
|
Observation |
|
|
|
0 |
Rifabutin 0.5 ug/mL Islt SlowMyco |
|
|
|
N |
|
AFB; Ansamycin; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Mycobutin; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis |
2.26 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42656-9 |
Rifabutin 2.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Rifabutin 2.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42656-9 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Rifabutin 2 ug/mL Islt SlowMy |
|
|
|
N |
|
2 ug/mL; Ansamycin; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Mycobutin; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42657-7 |
rifAMPin 1.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated rifAMPin 1.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42657-7 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated rifAMPin 1 ug/mL Islt SlowMyc |
|
|
|
N |
|
1 ug/mL; ANTIBIOTIC SUSCEPTIBILITIES; AST; c301; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Point in time; Random; RIF; Rifadin; Rifampicin; Rimactane; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42658-5 |
Streptomycin 10.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Streptomycin 10.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42658-5 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Streptomycin 10 ug/mL Islt Sl |
|
|
|
N |
|
10 ug/mL; Aminoglycosides; ANTIBIOTIC SUSCEPTIBILITIES; AST; c232; C295; Cidam est; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Novostrep; Point in time; Random; Solustrep; Streptocol; Strepto-fatol; Streptomyc; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42659-3 |
Streptomycin 2.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Streptomycin 2.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42659-3 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Streptomycin 2 ug/mL Islt Slo |
|
|
|
N |
|
2 ug/mL; Aminoglycosides; ANTIBIOTIC SUSCEPTIBILITIES; AST; c232; C295; Cidam est; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Novostrep; Point in time; Random; Solustrep; Streptocol; Strepto-fatol; Streptomyc; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
4266-3 |
Furosemide |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Furosemide [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4266-3 |
|
|
|
|
Observation |
|
|
|
0 |
Furosemide Dose |
|
|
|
Y |
|
c210; Dose med or substance; DRUG DOSES; Furj; LASIX; LASJ; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
42660-1 |
Alpha 2 laminin |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
Alpha 2 laminin [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
42660-1 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
A2 Laminin Tiss Ql ImStn |
|
|
|
N |
|
A2; A2 Laminin; Alfa; IHC; II; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; LM2; LM-2; Merosin; Ordinal; PATHOLOGY; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42661-9 |
Bacteria |
Prid |
Isolate |
Pt |
Nom |
PFGE |
|
ACTIVE |
Bacteria identified in Isolate by Pulsed-Field Gel Electrophoresis (PFGE) |
|
NAM |
DefinitionDescription |
|
|
|
"Indistinguishable" or "Different" by PFGE |
|
|
|
|
|
MICRO |
|
42661-9 |
|
PFGE |
|
|
Both |
|
|
|
0 |
Bacteria Islt PFGE |
|
|
|
N |
|
Bact; ID; Identity or presence; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Nominal; Point in time; Pulse Field Gel Electrophoresis; Pulsed-Field Gel Electrophoresis; Random |
2.78 |
2.16 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
42662-7 |
Benzodiazepines |
PrThr |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Benzodiazepines [Presence] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
Negative |
|
|
|
|
|
DRUG/TOX |
|
42662-7 |
|
|
|
|
Both |
|
|
|
0 |
Benzodiaz Bld Ql |
|
|
|
N |
|
Benz; Benzodiaz; Benzodiazepine; Blood; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42663-5 |
HLA-Cw locus |
Type |
Bld/Tiss |
Pt |
Nom |
|
|
ACTIVE |
HLA-Cw locus [Type] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
42663-5 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-Cw locus |
|
|
|
N |
|
Blood; Continuous wave; Genetics; Heredity; Heritable; HLA ANTIGEN; HLA-Cw; Human Leukocyte Antigen; Inherited; Nominal; Point in time; Random; Tissue; Tissue, unspecified; Typ; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types. |
0 |
42664-3 |
HLA-Cw |
Type |
Bld/Tiss |
Pt |
Nom |
|
|
ACTIVE |
HLA-Cw [Type] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
42664-3 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-Cw |
|
|
|
N |
|
Blood; Continuous wave; Genetics; Heredity; Heritable; HLA ANTIGEN; HLA-Cw; Human Leukocyte Antigen; Inherited; Nominal; Point in time; Random; Tissue; Tissue, unspecified; Typ; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types. |
0 |
42665-0 |
Dantron |
MCnt |
Stool |
Pt |
Qn |
|
|
ACTIVE |
Dantron [Mass/mass] in Stool |
|
MIN |
DefinitionDescription |
|
|
ug/g |
|
|
|
|
|
|
DRUG/TOX |
|
42665-0 |
|
|
|
|
Both |
|
|
|
0 |
Dantron Stl-mCnt |
|
|
|
N |
|
1,8-Dihydroxyanthraquinone; Bowel movement; Chrysazin; Danthron; DRUG/TOXICOLOGY; Drugs; Faecal; Faeces; Fecal; Feces; Mass content; Point in time; QNT; Quan; Quant; Quantitative; Random; Stl; Stool = Fecal |
2.3 |
2.16 |
|
|
|
|
|
|
|
ug/g |
|
|
|
0 |
42666-8 |
Fat.neutral |
Naric |
Plr fld |
Pt |
Qn |
Microscopy.light.HPF |
|
ACTIVE |
Fat.neutral [#/area] in Pleural fluid by Microscopy high power field |
|
MIN |
DefinitionDescription |
|
|
/HPF |
<60 droplets/HPF |
|
|
|
|
|
CHEM |
|
42666-8 |
|
Microscopy.light.HPF |
|
|
Both |
|
|
|
0 |
Neutral Fat #/area Plr HPF |
|
|
|
N |
|
#/area; Acylglycerol; Chemistry; LM; Micro; Micros; Microscopic; Neutral Fat; Number areic; Pleural; Pleural fluid; Point in time; QNT; Quan; Quant; Quantitative; Random; thoracentesis fluid |
2.7 |
2.16 |
|
|
|
|
|
|
|
/[HPF] |
|
|
|
0 |
42667-6 |
Fatty acids |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Fatty acids [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
42667-6 |
|
|
|
|
Both |
|
|
|
0 |
FA Ur Ql |
|
|
|
N |
|
Acd; Acid; Chemistry; Fatty acid; Lipid; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42668-4 |
Fatty acids |
PrThr |
Stool |
Pt |
Ord |
|
|
ACTIVE |
Fatty acids [Presence] in Stool |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
42668-4 |
|
|
|
|
Both |
|
|
|
0 |
FA Stl Ql |
|
|
|
N |
|
Acd; Acid; Bowel movement; Chemistry; Faecal; Faeces; Fatty acid; Fecal; Feces; Lipid; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Stl; Stool = Fecal |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |